isoxazoles has been researched along with Carcinoma, Papillary in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, W; Liu, J; Qin, Y; Sun, W; Wang, Z; Zhang, H; Zhang, T | 1 |
1 other study(ies) available for isoxazoles and Carcinoma, Papillary
| Article | Year |
|---|---|
HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; HSP90 Heat-Shock Proteins; Humans; Inhibitor of Apoptosis Proteins; Isoxazoles; Resorcinols; Signal Transduction; Survivin; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2017 |